The study analysed that the Herpes simplex virusinfections pipeline comprises of 20 drug candidates in different stages of
development.
As per the findings of the research, most of the drug
candidates are being developed to be administered by oral route.
Access More About This Research at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis
Many technologies are being developed that offer
promising innovative treatments which can control the progression of Herpes
simplex virus infections. The technologies include, but not limited to, Vector
based technology platform, AdenoVerse technology platform, Juvari’s technology
platform and Nanostat technology platform.
The research found that various companies have
collaborated for the development of Herpes simplex virus infections pipeline.
In June 2014, PaxVax Inc., entered into a research and development
collaboration with the University of California to develop a combination vaccine
to prevent genital herpes simplex virus infections.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Some of the key players
developing drugs for the treatment of Herpes virus simplex infections include
Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and others.
No comments:
Post a Comment